Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pritoxaximab, an antibody targeting Shiga Toxin Type 1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pinatuzumab, an antibody targeting CD22.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Parsatuzumab, an antibody targeting EGFL7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozanezumab, an antibody targeting RTN4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ocaratuzumab, an antibody targeting CD20.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lodelcizumab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lirilumab, an antibody targeting KIRD2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imgatuzumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dusigitumab, an antibody targeting IGF1 and IGF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tovetumab, an antibody targeting PDGFRA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Otlertuzumab, an antibody targeting CD37.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lifastuzumab, an antibody targeting SLC34A2.